^
Association details:
| Biomarker: | TP53 mutation |
|---|---|
| Cancer: | Chronic Lymphocytic Leukemia |
| Drug: | Epkinly (epcoritamab-bysp) (CD20 inhibitor, CD3 agonist) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Epcoritamab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia: Results From the Phase 1b/2 EPCORE CLL-1 Trial Expansion Cohort
Published date:
10/06/2023
Excerpt:
Among efficacy-evaluable patients with TP53 mutation and/or del(17p) alteration (n=12), ORR/CR rate was 67%/25%. Median time to response was 2.1mo (range,1.6–3.3), and median time to CR was 3.2mo (range, 1.6–10.8)….Preliminary efficacy findings show that epcoritamab SC induces high ORRs and encouraging CR rates in patients with heavily pretreated, high-risk R/R CLL.
Trial ID:
